Pfizer

Eli Lilly, TVM fund invests in Ixchelsis

Friday, August 9, 2013 01:14 PM

TVM Life Science Ventures VII, a collaboration between TVM and Eli Lilly to provide venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries, has announced the fund’s second investment in Ixchelsis, a clinical-stage biotechnology startup in the U.K. Ixchelsis plans to develop to proof-of-concept IX-01, an investigational compound, originally discovered at Pfizer’s U.K. R&D site, with the potential to treat the male sexual health indication premature ejaculation.

More... »

PharmAthene, Theraclone Sciences merge

Monday, August 5, 2013 11:58 AM

PharmAthene and Theraclone Sciences, a privately-held monoclonal antibody (mAb) discovery and development company, have signed a definitive merger agreement.

More... »

Pfizer to create separate internal, global innovative and value businesses

Monday, July 29, 2013 03:00 PM

Pfizer has announced plans to internally separate its commercial operations into three business segments, two of which will include innovative business lines and a third to include the value business line. 

More... »

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »

Pfizer invests $130 million in two Irish manufacturing sites

Friday, July 12, 2013 02:12 PM

Pfizer is investing $130 million in two of its Irish manufacturing sites, $100 million in the Grange Castle site in Dublin and $30 million in the Ringaskiddy site in Cork. 

More... »

InnovoCommerce, SAFE-BioPharma collaborate

Friday, June 28, 2013 02:02 PM

The global SAFE-BioPharma digital identity and signature standard is being incorporated into the InnovoCommerce eClinical product suite used by pharmaceutical companies for their enterprise and investigator portal initiatives. InnovoCommerce is a source of eClinical collaboration products and solutions. It also has joined SAFE-BioPharma Association’s Vendor Partner program.

More... »

Pfizer, GSK, Siemens and A*STAR form R&D consortium

Monday, June 24, 2013 03:13 PM

Pfizer Asia Pacific, GlaxoSmithKline and Siemens are founding members of the A*STAR R&D consortium program Innovative Processing of Specialties and Pharmaceuticals (iPSP). Launched by A*STAR's Institute of Chemical and Engineering Sciences (ICES), the consortium is a platform for pharmaceutical and specialty chemicals industry companies to address costs, regulatory compliance and responsiveness in production and processes to bring drugs to markets.

More... »

Astellas Pharma joins SAFE-BioPharma

Friday, June 21, 2013 01:21 PM

Astellas Pharma has joined the SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the global SAFE-BioPharma digital identity and signature standard. As a member, Astellas is able to utilize the SAFE-BioPharma standard. It is the first Japanese pharmaceutical company to become a member.

More... »

Pfizer announces Zoetis split-off plan

Friday, June 14, 2013 01:42 PM

Pfizer intends to split off its remaining interest in Zoetis through an exchange offer. Zoetis, formerly Pfizer's animal health business, completed its initial public offering (IPO) in February 2013. Pfizer shareholders can exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer.

More... »

CytomX, Pfizer collaborate to develop and commercialize in oncology

Friday, June 7, 2013 01:54 PM

CytomX Therapeutics, a biotechnology company developing a new generation of targeted antibody therapeutics, has entered into a global collaboration with Pfizer to develop and commercialize multiple Probody-Drug Conjugates (PDCs).

More... »